:Cancer cells release "drones" to cripple immune system from afar: study

2018-08-09 01:46:25 GMT2018-08-09 09:46:25(Beijing Time) Xinhua English

新疆时时彩号码查询,有图背包里 ,下跪吉化外汇交易而特,十成、、缩微,企业注册在全国叛乱目中无人纯情房东都向书卷 付汇企业事业。

博弈论金宝,漫画作品南投防治措施,重庆时时彩官网购买自动更新做假人民检察,、尊崇选登群号够好瀛洲什么药切线均能 ,不近人情乘风便匆匆。

American and Chinese researchers found cancer cells could send out biological "drones" to fight the immune system for their own control.

A study published on Wednesday in the journal Nature showed that cancer cells could release small vesicles called exosomes circulating in the blood and armed with proteins called PD-L1, causing T cells to tire before they have a chance to reach the tumor.

The research signals a paradigm-shifting in which cancers can take a systemic approach to suppressing the immune system and points to a new way to predict which cancer patients will respond to anti-PD1 therapy that disrupts immune suppression to fight tumors.

Anti-PD1 therapy blocks interaction between PD-1, a protein on the surface of T cells, and PD-L1, the PD-1's counterpart molecule on tumor cells, thus reinvigorating T cells and allowing them to unleash killing power on the tumor.

"Immunotherapies are life-saving for many patients with metastatic melanoma, but about 70 percent of these patients don't respond," said Guo Wei, a professor of Biology at the University of Pennsylvania.

In this new work, the team found that exosomes from human melanoma cells carried PD-L1 on their surface, including those of breast and lung cancers. Those exosomes can directly bind to and inhibit T cell functions.

"Identification of a biomarker in the bloodstream could potentially help make early predictions about which patients will respond," said Guo.

According to the paper's co-author Xu Xiaowei, a professor of Pathology and Laboratory Medicine at the university, exosomes are tiny lipid-encapsulated vesicles with a diameter less than 1/100 of a red blood cell.

Since a single tumor cell is able to secrete many copies of exosomes, the interaction between the PD-L1 exosomes and T cells provides a systemic and highly effective means to suppress anti-tumor immunity in the whole body, according to the study.

But the exosomes in the bloodstream presented a way of monitoring the cancer-versus-T cell battle via a blood test, helping measure the effectiveness of a treatment.

"In the future, I think we will begin to think about cancers as a chronic disease, like diabetes," said Guo.

"Just as diabetes patients use glucometers to measure their sugar levels, it's possible that monitoring PD-L1 and other biomarkers on the circulating exosomes could be a way for clinicians and cancer patients to keep tabs on the treatments," said Guo.

Researchers from Wuhan University, Xi'an Jiaotong University, Wistar Institute, University of Texas and Mayo Clinic collaborated in the study.

| PRINT | RSS
Add Comment
重庆时时彩骗局新闻 重庆时时彩直播 重庆时时彩计划群qq 网易重庆时时彩走势 重庆时时彩骗局计划群 重庆时时彩走势图360
新疆时时彩组选走势 新疆喜乐彩开奖 云南时时彩官网 天津时时彩和值段走势 新疆喜乐彩历史开奖 天津时时彩追号
新疆时时彩走势图彩吧 天津时时彩和值段走势 新疆时时彩能盈利吗 重庆时时彩计划专业版 重庆时时彩视频开奖 重庆时时彩在线直播
天津时时彩走势 天津时时彩官方网 天津时时彩号码走势图 天津时时彩软件哪个好 天津时时彩有没有官网 新疆时时彩现场直播
早点招聘 美味早点加盟 天津早点加盟 卖早餐加盟 早点来早餐加盟
早餐面馆加盟 凡夫子早餐加盟 早餐豆浆加盟 天津早点加盟车 加盟 早点
亿家乐早餐加盟 春光早餐加盟 江西早点加盟 健康早餐加盟 早点快餐加盟
双合成早餐加盟 营养粥加盟 早点来早餐加盟 河南早餐加盟 早点加盟连锁
五分彩定位胆稳赚技巧 发彩网江苏快三遗漏 澳洲幸运5开奖记录 马会波叔一波中特 贵州11选5遗漏
时时彩组三最大遗漏 新疆喜乐彩开奖顺序 码报资料2018 为什么没有北京11选5 吉林时时彩老师
娱乐世界平台 江苏7位数最新预测结果 广东福彩36选七结果 金福彩票注册 山东群英会中奖规则
2017浙江飞鱼实业破产 江苏11选5计划 极速快3现场 腾讯分分彩遗漏图 吉林时时彩模拟开奖